NASDAQ:AGEN - Agenus Stock Price, News, & Analysis

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Agenus (NASDAQ:AGEN) Frequently Asked Questions

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

How were Agenus' earnings last quarter?

Agenus Inc (NASDAQ:AGEN) issued its earnings results on Thursday, August, 9th. The biotechnology company reported ($0.24) EPS for the quarter, beating the Zacks' consensus estimate of ($0.40) by $0.16. View Agenus' Earnings History.

When is Agenus' next earnings date?

Agenus is scheduled to release their next quarterly earnings announcement on Tuesday, November 6th 2018. View Earnings Estimates for Agenus.

Who are some of Agenus' key competitors?

Some companies that are related to Agenus include Acorda Therapeutics (ACOR), Fate Therapeutics (FATE), BAVARIAN NORDIC/S (BVNRY), Heska (HSKA), BioCryst Pharmaceuticals (BCRX), Mesoblast (MESO), Novavax (NVAX), Scholar Rock (SRRK), Voyager Therapeutics (VYGR), Vericel (VCEL), Nightstar Therapeutics (NITE), NanoString Technologies (NSTG), La Jolla Pharmaceutical (LJPC), Replimune Group (REPL) and Translate Bio (TBIO).

Who are Agenus' key executives?

Agenus' management team includes the folowing people:

• Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 65)
• Ms. Christine M. Klaskin, Principal Accounting Officer & VP of Fin. (Age 52)
• Dr. Alexander R. Duncan, CTO & Head of Research (Age 56)
• Dr. Robert B. Stein, Sr. R&D Advisor (Age 67)
• Dr. Christian Cortis, Chief Strategy Officer & Head of Fin. (Age 50)

How do I buy shares of Agenus?

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $1.98.

How big of a company is Agenus?

Agenus has a market capitalization of $242.42 million and generates $42.88 million in revenue each year. The biotechnology company earns $-120,690,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Agenus employs 255 workers across the globe.

What is Agenus' official website?

The official website for Agenus is http://agenusbio.com.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]